Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06025214
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Phase 1
Active, not recruiting
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05982990
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Phase 1
Active, not recruiting
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05697003
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Phase 3
Recruiting
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 451
- Registration Number
- NCT05664061
- Locations
- 🇬🇷
BECRO Ltd., Athens, Greece
A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
Phase 1
- Conditions
- AsthmaBioequivalence
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05397834
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Phase 1
- Conditions
- BioequivalenceAsthma
- Interventions
- Drug: TestDrug: Reference
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05085587
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
Phase 1
- Conditions
- AsthmaBioequivalence
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05021887
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Pooled Analysis FP_SX_250_50
Completed
- Conditions
- Asthma
- Interventions
- Drug: TestDrug: Reference
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT04790838
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Phase 1
- Conditions
- BioequivalenceAsthma
- Interventions
- Drug: TestDrug: Reference
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04746040
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 451
- Registration Number
- NCT04665895
- Locations
- 🇬🇷
BECRO Ltd., Athens, Greece
© Copyright 2025. All Rights Reserved by MedPath